Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Intellia Therapeutics Inc

Healthcare US NTLA

14.83USD
1.81(13.90%)

Last update at 2026-06-04T18:11:00Z

Day Range

13.1215.49
LowHigh

52 Week Range

19.3747.48
LowHigh

Fundamentals

  • Previous Close 13.02
  • Market Cap2343.39M
  • Volume6860799
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-507.89798M
  • Revenue TTM52.60M
  • Revenue Per Share TTM0.58
  • Gross Profit TTM -367.85800M
  • Diluted EPS TTM-5.37

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -474.18600M -267.89200M -134.23100M -99.53300M -85.34300M
Minority interest - - - - -
Net income -490.20800M -259.71800M -125.56800M -92.69800M -85.34300M
Selling general administrative 90.31M 71.10M 44.17M 41.06M 32.19M
Selling and marketing expenses - - - - -
Gross profit 52.12M 33.05M 57.99M 43.10M 30.43M
Reconciled depreciation 7.57M 6.89M 6.31M 5.59M 4.46M
Ebit -458.16400M -274.74100M -142.89400M -106.36800M -95.33400M
Ebitda -444.67900M -267.85000M -136.58300M -100.78100M -90.87000M
Depreciation and amortization 13.48M 6.89M 6.31M 5.59M 4.46M
Non operating income net other -17.65900M 0.04M 2.09M 7.12M 5.50M
Operating income -458.16400M -267.85000M -136.58300M -106.36800M -90.87000M
Other operating expenses 510.29M 300.90M 194.58M 149.47M 121.30M
Interest expense 8.54M 6.89M 2.35M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 8.54M 1.28M 2.35M 6.83M 5.53M
Net interest income 8.54M 1.28M 2.35M 6.83M 5.53M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 16.02M -8.17400M -8.66300M -6.83500M 5.53M
Total revenue 52.12M 33.05M 57.99M 43.10M 30.43M
Total operating expenses 510.29M 300.90M 194.58M 149.47M 121.30M
Cost of revenue - - - 108.41M 89.11M
Total other income expense net -16.02200M -0.04200M 2.35M 6.83M 5.53M
Discontinued operations - - - - -
Net income from continuing ops -474.18600M -267.80800M -134.49100M -99.53300M -85.34300M
Net income applicable to common shares -474.18600M -267.89200M -134.23100M -99.53300M -85.34300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1300.98M 1520.11M 1294.46M 676.32M 334.28M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 49.65M 20.41M 18.58M 17.02M 5.13M
Total liab 250.81M 284.53M 254.22M 149.25M 64.40M
Total stockholder equity 1050.17M 1235.58M 1040.24M 527.07M 269.88M
Deferred long term liab - - - - -
Other current liab 67.02M 60.88M 43.31M 25.55M 13.27M
Common stock 0.00900M 0.00900M 0.00700M 0.00700M 0.00500M
Capital stock 0.00900M 0.00900M 0.00700M 0.00700M 0.00500M
Retained earnings -1658.37900M -1177.18700M -703.00100M -435.10900M -300.87800M
Other liab - 43.96M 63.48M 51.39M 16.14M
Good will - - - - -
Other assets - 15.73M 4.76M 4.75M 2.92M
Cash 226.75M 523.51M 123.41M 160.02M 57.23M
Cash and equivalents - - - - -
Total current liabilities 115.21M 126.55M 125.83M 64.25M 35.63M
Current deferred revenue 22.14M 43.84M 63.76M 22.54M 12.67M
Net debt -111.40200M -392.80300M -49.38300M -120.71500M -38.85100M
Short term debt 18.60M 16.68M 9.11M 5.70M 5.75M
Short long term debt - - - - -
Short long term debt total 115.35M 130.70M 74.02M 39.30M 18.38M
Other stockholder equity 2710.80M 2420.22M 1745.87M 962.17M 570.49M
Property plant equipment - 27.92M 20.97M 15.94M 37.13M
Total current assets 998.33M 1216.80M 769.30M 597.37M 289.48M
Long term investments 154.51M 142.32M 425.05M 0.00000M 4.75M
Net tangible assets - 1369.53M 1168.63M 612.07M 269.88M
Short term investments 685.48M 669.12M 625.28M 437.35M 222.50M
Net receivables 36.46M 3.77M 2.03M 2.13M 4.62M
Long term debt - - - - -
Inventory - -69.33800M -337.36100M -19.14600M -
Accounts payable 7.45M 5.15M 9.65M 10.46M 3.94M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.25800M -7.46100M -2.63200M 0.00100M 0.26M
Additional paid in capital - - - - -
Common stock total equity - 0.00900M 0.00700M 0.00700M 0.00500M
Preferred stock total equity - - - - -
Retained earnings total equity - -1177.18700M -703.00100M -435.10900M -300.87800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 72.98M 87.69M 23.89M 2.92M
Deferred long term asset charges - - - - -
Non current assets total 302.65M 303.32M 525.16M 78.95M 44.80M
Capital lease obligations 115.35M 130.70M 74.02M 39.30M 18.38M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 160.31M -535.02200M -210.90200M 31.97M -254.55500M
Change to liabilities 11.34M 17.79M 18.09M 4.19M 2.86M
Total cashflows from investing activities 160.31M -550.77800M -214.48700M 25.18M -260.78200M
Net borrowings - - - - -
Total cash from financing activities 582.96M 736.69M 371.78M 76.43M 40.22M
Change to operating activities 15.91M 7.82M 4.86M 1.65M 3.96M
Net income -474.18600M -267.89200M -134.23100M -99.53300M -85.34300M
Change in cash 409.98M -39.12000M 107.38M -1.63000M -281.82200M
Begin period cash flow 125.49M 164.61M 57.23M 58.86M 340.68M
End period cash flow 535.46M 125.49M 164.61M 57.23M 58.86M
Total cash from operating activities -333.28700M -225.03000M -49.91200M -103.24000M -61.25700M
Issuance of capital stock 565.79M 693.57M 358.65M 72.26M 28.97M
Depreciation 7.57M 6.89M 6.31M 5.59M 4.46M
Other cashflows from investing activities -44.68200M -3.00000M - 31.97M 0.13M
Dividends paid - - - - -
Change to inventory - 7.82M 4.86M 1.65M 3.96M
Change to account receivables -1.73700M 0.10M 2.49M 2.93M 2.92M
Sale purchase of stock 582.96M 1861.02M 371.78M 76.43M 40.22M
Other cashflows from financing activities 17.17M 43.12M 13.13M 4.18M 11.25M
Change to netincome 171.79M 45.68M 19.94M 15.09M 17.12M
Capital expenditures 58.39M 12.76M 3.58M 6.79M 6.36M
Change receivables -1.73700M 0.10M 2.49M 2.93M 2.92M
Cash flows other operating -52.07100M -43.72900M 36.95M -27.77800M -2.60400M
Exchange rate changes - - - - -
Cash and cash equivalents changes 409.98M -39.12000M 107.38M -1.63000M -281.82200M
Change in working capital -53.87300M -22.90400M 57.53M -20.66100M 3.18M
Stock based compensation 91.40M 47.01M 19.90M 15.09M 17.05M
Other non cash items 95.80M 2.94M 0.57M -3.72400M -0.60100M
Free cash flow -391.67700M -237.78600M -53.49700M -110.03400M -67.61500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NTLA
Intellia Therapeutics Inc		 1.81 13.90% 14.83 - - 64.30 2.22 42.39 -3.0367
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics Inc

40 Erie Street, Cambridge, MA, United States, 02139

Key Executives

Name Title Year Born
Dr. John M. Leonard M.D. Pres, CEO & Director 1957
Mr. Glenn G. Goddard CPA Exec. VP, CFO & Treasurer 1971
Dr. Laura Sepp-Lorenzino Ph.D. Exec. VP & Chief Scientific Officer 1961
Mr. James E. Basta Esq., J.D. Exec. VP, Gen. Counsel & Corp. Sec. 1966
Dr. David Lebwohl M.D. Exec. VP & Chief Medical Officer 1955
Mr. Nessan Bermingham Ph.D. Founder & Member of Scientific Advisor Board 1973
Dr. Rachel E. Haurwitz Ph.D. Co-Founder 1986
Dr. Andrew May Founder and Member of Scientific Advisor Board NA
Dr. Jennifer A. Doudna Ph.D. Founder & Member of Scientific Advisor Board 1964
Dr. Derrick J. Rossi Ph.D. Founder & Member of Scientific Advisor Board NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.